World Health Organization. World Malaria Report 2022. https://www.who.int/ teams/global-malaria-programme/reports/world-malaria-report-2022.
Sato S. Plasmodium—a brief introduction to the parasites causing human malaria and their basic biology. J Physiol Anthropol. 2021;40:1. https://doi.org/10.1186/s40101-020-00251-9.
Kelly-Hope LA, Hemingway J, McKenzie FE. Environmental factors associated with the malaria vectors Anopheles gambiae and Anopheles funestus in Kenya. Malar J. 2009;8:1. https://doi.org/10.1186/1475-2875-8-268.
Ericsson, C.D. Steffen R., Stauffer W., Fischer P.R. Diagnosis and Treatment of Malaria in Children, Clin Infect Dis 2003; 37:10:1340–1348. https://academic.oup.com/cid/article/37/10/1340/451166.
Wellems TE, Plowe C. Chloroquine-resistant Malaria. J Infect Dis. 2001;184:770–776. http://jid.oxfordjournals.org/.
Neill PM, Ward SA, Berry NG, et al. A medicinal chemistry perspective on 4-aminoquinoline Antimalarial drugs. Curr Top Med Chem. 2006;6:479–507.
Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol. 2006;61:246–255. https://doi.org/10.1111/j.1365-2125.2005.02529.x.
Mcosker CC, Fitzpatrick PM. Nitrofurantoin: mechanism of action and implications for resistance development in common uropathogens. J Antimicrob Chemother.1994;33. http://jac.oxfordjournals.org/.
See S, Ginzburg R. Skeletal muscle relaxants. Pharmacotherapy. 2008;28:207–213. https://doi.org/10.1592/phco.28.2.207.
Harris MG, Stephen G, Faulds CD, Chrisp P. Nilutamide a review of its Pharmacodynamic and Pharmacokinetic properties, and therapeutic efficacy in prostate cancer. Drugs Aging. 1993;3:170.
Abrol R, Page RL. Azimilide dihydrochloride: a new class III anti-arrhythmic agent. Expert Opin Invest Drugs. 2000;9:2705–2715. http://www.ashley-pub.com.
Pitts NE, Vreeland F, Shaw GL, et al. Clinical experience with sorbinil-an aldose reductase inhibitor. Metabolism. 1986;35:96–100.
Meyers MJ, Tortorella MD, Xu J, et al. Evaluation of aminohydantoins as a novel class of antimalarial agents. ACS med Chem Lett. 2014;5:89–93. https://doi.org/10.1021/ml400412x.
Chin E, Tan S, Liew S, Kurz T. Synthesis and Characterization of amino acidderived hydantoins. Malays J Chem. 2021;23:2.
Zakiah M, Syarif R, Mustofa M, Jumina J, Fatmasari N, Sholikhah E. In vitro antiplasmodial, heme Polymerization, and cytotoxicity of hydroxyxanthone derivatives. J Trop Med. 2021:1–11.
Amit A., Bandana K. T., Rawat M. S. M. ‘Synthesis, Antibacterial Screening and Theoretical Molecular Properties Prediction of Hydantoin-chalcone Conjugates.’ 2014;91:1525-1531.
Fujisaki F., Aki H., Naito A., Fukami E., Kashige N., Miake F., Sumoto K., 2014. Synthesis of New 5-Substituted Hydantoins and Symmetrical Twin-Drug Type Hydantoin Derivatives. Chem Pharm Bull 2014; 62: 5: 429-438.
Hidayat I., Thu Y., St. C Black D., Read R. Biological evaluation of certain substituted hydantoins and benzalhydantoins against microbes. IOP Conference Series: Mater Sci Eng, 2016;107:012058.
Liu J, Zhang K, Mai X, et al. Synthesis, anticancer evaluation and docking study of 3- benzyloxyhydantoin derivatives. J Med Chem. 2016;12:37–47.
Su M, Xia D, Teng P, et al. Membrane-active hydantoin derivatives as antibiotic agents. J Med Chem. 2017;60:8456–8465.
Zhang M, Liang Y, Li H, Liu M, Wang Y. Design, synthesis, and biological evaluation of hydantoin bridged analogues of combretastatin A-4 as potential anticancer agents. Bioorg Med Chem. 2017;25:6623–6634.
Ovung A, Bhattacharyya J. Sulfonamide drugs: structure, antibacterial property, toxicity, and biophysical interactions. Biophys Rev. 2021;29:259–272. https://doi.org/10.1007/s12551-021-00795-9.
Thach TD, Nguyen TMT, Nguyen TAT, et al. Synthesis and antimicrobial, antiproliferative and anti-inflammatory activities of novel 1,3,5-substituted pyrazoline sulfonamides. Arab J Chem. 2021;14:103408–103419. https://doi.org/10.1016/j.arabjc.2021.103408.
Li JJ, Anderson D, Burton EG, et al. 1,2-Diarylcyclopentenes as selective cyclooxygenase-2 inhibitors and orally active anti-inflammatory agents. J Med Chem. 1995;38:4570–4578. https://doi.org/10.1021/jm00022a023.
Ahmed, N.M., Lotfallah, A. H., Gaballah, M. S., Awad, S. M., Soltan, M. K. Novel 2- thiouracil-5-sulfonamide derivatives: Design, synthesis, molecular docking, and biological evaluation as antioxidants with 15-LOX inhibition. Molecules 2023; 28: 1925-1948. https://doi.org/10.3390%2Fmolecules28041925.
Sowa T, Menju T, Chen-Yoshikawa FT, et al. Hypoxia-inducible factor 1 promotes chemoresistance of lung cancer by inducing carbonic anhydrase IX expression. Cancer Med. 2017;6:288–297. https://doi.org/10.1002/cam4.991.